Ascendis Pharma A/S

SecurityASND / Ascendis Pharma A/S
InstitutionONEQ - Fidelity Nasdaq Composite Index Tracking Stock
Latest Disclosed Ownership14,208 shares
Latest Disclosed Value $ 2,313,630
ONEQ - Fidelity Nasdaq Composite Index Tracking Stock reports 0.50% increase in ownership of ASND / Ascendis Pharma A/S

On July 24, 2025 - ONEQ - Fidelity Nasdaq Composite Index Tracking Stock filed a NPORT-P form disclosing ownership of 14,208 shares of Ascendis Pharma A/S (US:ASND) valued at $2,313,631 USD as of May 31, 2025. The entity filed a previous NPORT-P on April 25, 2025 disclosing 14,138 shares of Ascendis Pharma A/S. This represents a change in shares of 0.50% during the quarter. The current value of the position is $2,990,074 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-07-24 2025-05-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 14,208 70 0.50 2,314 4.52 0.0306
2025-04-25 2025-02-28 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 14,138 378 2.75 2,214 18.22 0.0298
2025-01-27 2024-11-30 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 13,760 -1,619 -10.53 1,872 -12.07 0.0254
2024-10-29 2024-08-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 15,379 1,095 7.67 2,129 10.37 0.0315
2024-07-26 2024-05-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 14,284 175 1.24 1,930 -7.44 0.0306
2024-04-24 2024-02-29 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 14,109 217 1.56 2,085 49.39 0.0348
2024-01-24 2023-11-30 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 13,892 21 0.15 1,395 2.65 0.0268
2023-10-27 2023-08-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 13,871 210 1.54 1,360 14.39 0.0266
2023-07-26 2023-05-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 13,661 42 0.31 1,188 -21.43 0.0256
2023-04-27 2023-02-28 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 13,619 315 2.37 1,513 -7.64 0.0370
2023-01-26 2022-11-30 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 13,304 329 2.54 1,637 40.88 0.0409
2022-10-26 2022-08-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 12,975 2,408 22.79 1,162 30.12 0.0291
2022-07-29 2022-05-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 10,567 312 3.04 893 -22.48 0.0228
2022-04-28 2022-02-28 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 10,255 156 1.54 1,153 -16.70 0.0267
2022-01-25 2021-11-30 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 10,099 258 2.62 1,384 -10.31 0.0289
2021-10-26 2021-08-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 9,841 183 1.89 1,542 18.89 0.0338
2021-07-22 2021-05-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 9,658 36 0.37 1,298 -13.01 0.0323
2021-04-23 2021-02-28 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 9,622 540 5.95 1,491 -2.68 0.0388
2021-01-20 2020-11-30 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 9,082 -12 -0.13 1,532 13.73 0.0458
2020-10-16 2020-08-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 9,094 327 3.73 1,348 5.65 0.0416
2020-07-20 2020-05-31 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 8,767 252 2.96 1,276 14.86 0.0498
2020-04-24 2020-02-29 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 8,515 1,198 16.37 1,110 31.83 0.0495
2020-01-16 2019-11-30 NP ASCENDIS PHARMA AS SPON ADR EC US04351P1012 7,317 7,317 843 0.0383
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.